PCPs Learning to Use GLP-1 RAs in Patients with T2D to Improve Their Care: A 3-Part CME Podcast Series

Podcast 2

Release Date: May 3, 2024

Expiration Date: May 3, 2025

Name*
Profession*
N/A if not applicable
MAX OF 0.50

POST TEST

1. Patients with type II diabetes and an elevated risk for atherosclerotic cardiovascular disease should be considered for __________ therapy regardless of hemoglobin A1c.*
2. GLP-1 receptor agonists should be considered in patients with type II diabetes and high ________ risk OR patients without diabetes who are overweight/obese and have a history of cardiovascular disease.*
3. Newer data suggest a significant reduction in cardiovascular events with GLP-1 agonist therapy in patients who are ________________ and have a prior history of heart disease.*

Please try again!

Sorry, you did not reach the passing score.  Please click "Previous" and try again!

PROGRAM EVALUATION

After participating in this activity I am better prepared to:*
After participating in this activity I am better prepared to:
  Strongly Agree Agree Disagree Strongly Disagree
Interpret the mechanism of action of GLP-1 receptor agonists and their effects on multiple organ systems.
Individualize GLP-1 RA selection based on the patient's presentation, needs for glucose reduction, cardiovascular risk, weight, administration route, safety and tolerability concerns, etc.
Relate the clinical data for GLP-1 RAs on people with T2D and how PCPs implement national guidelines pertaining to the use of GLP-1 RAs for reduction of hyperglycemia.
The activity was appropriate and met my educational needs.*
The educational materials were effective.*
The learning activities were effective and incorporated active learning methods.*
The content provided a fair and balanced coverage of the topic.*
The faculty was knowledgeable, effective and free of bias.*
The following speaker(s) demonstrated experiential knowledge of the topic.*
The following speaker(s) demonstrated experiential knowledge of the topic.
  Strongly Agree Agree Disagree Strongly Disagree
Neha Pagidipati MD MPH
The content was free of commercial bias.*
Based on information presented in the activity, I will:*
As a result of this course, I will make changes to my practice in these categories:*